-
11.发明专利
公开(公告)号：CO6930310A2
公开(公告)日：2014-04-28
申请号：CO14082286
申请日：2014-04-15
Applicant: UCB PHARMA SA
-
公开(公告)号：AU2013203712A1
公开(公告)日：2013-05-02
申请号：AU2013203712
申请日：2013-04-11
Applicant: BIOGEN MA INC , UCB PHARMA SA
Inventor： BURKLY LINDA , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , ADAMS RALPH , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE , TAYLOR FREDERICK R , HSU YEN-MING , SU LIHE
IPC: C07K16/28 , A61K39/395 , C12N15/13 , C12N15/63
Abstract: Abstract This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD 154-CD40 interactions. FIGURE 19: inhibition of IgG Immune Response to Tetanus Toxoid in Cynomolgus Monkeys Primary Immune Response to TT -
-
公开(公告)号：DOP2009000221A
公开(公告)日：2009-10-31
申请号：DO2009000221
申请日：2009-09-18
Applicant: BIOGEN IDEC INC , UCB PHARMA SA
Inventor： BURKLY LINDA C , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , HSU YEN-MING , SU LIHE , TAYLOR FREDERICK R , ADAMS RALPH , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE
Abstract: Esta invencion proporciona proteinas de union, que incluyen anticuerpos, derivados de anticuerpo, y fragmentos de anticuerpo, que especificamente se unen a la proteina CD154 (CD40L). Esta invencion tambien proporciona un anticuerpo quimerico, humanizado o completamente humano, derivado de anticuerpo o fragmento de anticuerpo que especificamente se une a un epitopo al cual se une un fragmento humanizado que comprende una secuencia de cadena pesada variable de acuerdo con SEC ID NO: 1 Y comprende una secuencia de cadena ligera variable de acuerdo con SEC ID NO: 2. Las proteinas de union CD154 de esta invencion pueden producir una funcion efectora reducida con relacion a un segundo anticuerpo anti-CD154. Las proteinas de union CD154 de la invencion son utiles en metodos de diagnostico y terapeuticos, tales como en el tratamiento y prevencion de enfermedades que incluyen las que involucran respuestas inmunitarias indeseables que estan mediadas por las interacciones de CD154-CD40.
-
公开(公告)号：MX2009010120A
公开(公告)日：2009-10-19
申请号：MX2009010120
申请日：2008-03-21
Applicant: UCB PHARMA SA
Inventor： GARBER ELLEN A , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ADAMS RALPH , BURKLY LINDA C , FERRANT-ORGETTAS JANINE L , HSU YEN-MING , SU LIHE , TAYLOR FREDERICK R , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE
IPC: A61K39/395 , C07K16/28 , C12N15/13 , C12N15/63
Abstract: Esta invención proporciona proteínas de unión, que incluyen anticuerpos, derivados de anticuerpo, y fragmentos de anticuerpo, que específicamente se unen a la proteína CD154 (CD40L). Esta invención también proporciona un anticuerpo quimérico, humanizado o completamente humano, derivado de anticuerpo o fragmento de anticuerpo que específicamente se une a un epítopo al cual se une un fragmento Fab humanizado que comprende una secuencia de cadena pesada variable de acuerdo con SEC ID NO: 1 y comprende una secuencia de cadena ligera variable de acuerdo con SEC ID NO: 2. Las proteínas de unión CD154 de esta invención pueden producir una función efectora reducida con relación a un segundo anticuerpo anti-CD154. Las proteínas de unión CD154 de la invención son útiles en métodos de diagnóstico y terapéuticos, tales como en el tratamiento y prevención de enfermedades que incluyen las que involucran respuestas inmunitarias indeseables que están mediadas por las interacciones de CD154-CD40.
-
公开(公告)号：EA032770B1
公开(公告)日：2019-07-31
申请号：EA201492101
申请日：2013-05-13
Applicant: UCB PHARMA SA
Inventor： FINNEY HELENE MARGARET , LAWSON ALASTAIR DAVID GRIFFITHS , SHAW STEVAN GRAHAM , SMITH BRYAN JOHN , TYSON KERRY LOUISE , KEVORKIAN LARA , MEIER CHRISTOPH , SARKAR KAUSHIK , ATHERFOLD PAUL ALAN
Abstract: Изобретениеотноситсяк антителампротив FcRn иихфрагментам, квыделеннымпоследовательностямДНК, кодирующимуказанныеантителаи ихфрагменты, квекторуэкспрессиии клонирования, кклетке-хозяинудляполученияуказанныхантител, кфармацевтическойкомпозиции, содержащейуказанныеантитела, кприменениюантители композициидлялечениясостояний, связанныхс патогеннымиаутоантителами IgG, такихкакмиастениягравис, пузырчаткаобыкновенная, оптиконевромиелит, синдромГийена-Барре, волчанка, идиопатическаятромбоцитопеническаяпурпураи тромботическаятромбоцитопеническаяпурпура.
-
Patent Agency Ranking
公开(公告)号：NZ702457A
公开(公告)日：2016-09-30
申请号：NZ70245713
申请日：2013-05-13
Applicant: UCB PHARMA SA
Inventor： LAWSON ALASTAIR DAVID GRIFFITHS , TYSON KERRY LOUISE , KEVORKIAN LARA , MEIER CHRISTOPH , SARKAR KAUSHIK , ATHERFOLD PAUL ALAN , FINNEY HELENE MARGARET , SHAW STEVAN GRAHAM , SMITH BRYAN JOHN
Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
-
公开(公告)号：ZA201402760B
公开(公告)日：2016-03-30
申请号：ZA201402760
申请日：2014-04-15
Applicant: UCB PHARMA SA
Inventor： COX MATTHEW , MACKENZIE BRENDON , FISHER NICOLA LOUISE , PAYNE ANDREW CHARLES , PAGE MATTHEW JON TIMOTHY , COMPSON JOANNE ELIZABETH , HERVE KARINE JEANNINE MADELEINE , KNIGHT DAVID EDWARD ORMONDE , TYSON KERRY LOUISE , LIGHTWOOD DANIEL JOHN , HUMPHREYS DAVID PAUL
Abstract: This present invention describes the derivation and selection of antibodies capable of neutralising the major exotox-in; TcdA of Clostridium difficile. The invention also describes novel neutralisation and antigen binding properties of in-dividual Mabs and mixtures thereof.
-
公开(公告)号：AU2012307157A1
公开(公告)日：2014-04-24
申请号：AU2012307157
申请日：2012-09-10
Applicant: UCB PHARMA SA
Inventor： HUMPHREYS DAVID PAUL , LIGHTWOOD DANIEL JOHN , TYSON KERRY LOUISE , KNIGHT DAVID EDWARD ORMONDE , HERVE KARINE JEANNINE MADELEINE , COMPSON JOANNE ELIZABETH , PAGE MATTHEW JON TIMOTHY , PAYNE ANDREW CHARLES , FISHER NICOLA LOUISE , MACKENZIE BRENDON , COX MATTHEW
Abstract: This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of
-
公开(公告)号：AU2008232409B2
公开(公告)日：2013-06-20
申请号：AU2008232409
申请日：2008-03-21
Applicant: BIOGEN IDEC INC , UCB PHARMA SA
Inventor： GARBER ELLEN A , POPPLEWELL ANDREW GEORGE , TAYLOR FREDERICK R , ROBINSON MARTYN KIM , SU LIHE , FERRANT-ORGETTAS JANINE L , ADAMS RALPH , SHOCK ANTHONY , BURKLY LINDA C , HSU YEN-MING , BROWN DEREK THOMAS , TYSON KERRY LOUISE
IPC: C07K16/28 , A61K39/395 , C12N15/13 , C12N15/63
Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
-
公开(公告)号：CA2848611A1
公开(公告)日：2013-03-21
申请号：CA2848611
申请日：2012-09-10
Applicant: UCB PHARMA SA
Inventor： HUMPHREYS DAVID PAUL , LIGHTWOOD DANIEL JOHN , TYSON KERRY LOUISE , KNIGHT DAVID EDWARD ORMONDE , HERVE KARINE JEANNINE MADELEINE , COMPSON JOANNE ELIZABETH , PAGE MATTHEW JON TIMOTHY , PAYNE ANDREW CHARLES , FISHER NICOLA LOUISE , MACKENZIE BRENDON , COX MATTHEW
Abstract: This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of Clostridium difficile. The invention also describes novel neutralisation and antigen binding properties of individual Mabs and mixtures thereof.
-
-
-
-
-
-
-
-
-
Search Results
59
records
(took 0.023 seconds)
